Shellback Capital’s Intellia Therapeutics NTLA Stock Holding History

Shellback Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-121,903	Closed	-$2.34M	–	110
2017 Q4	$2.34M	Buy	+121,903	New	+$2.81M	0.17%	75

Other funds holding NTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Shellback Capital's NTLA Position: Q1 2018 in Review

Shellback Capital sold out of Intellia Therapeutics (NTLA) in Q1 2018, closing a stake of 121,903 shares — an estimated $2.34M sold.

Shellback Capital first reported a position in NTLA in Q4 2017 and held it in 1 quarter. The position peaked at $2.34M in Q4 2017. 130 funds tracked by Wall St. Rank hold NTLA as of Q1 2018.

Shellback Capital reported no remaining Intellia Therapeutics position as of Q1 2018 after selling out during the quarter.
Shellback Capital sold 121,903 Intellia Therapeutics shares in Q1 2018, an estimated $2.34M.
Shellback Capital first reported a position in Intellia Therapeutics in Q4 2017 and held it in 1 quarter.
Shellback Capital's Intellia Therapeutics position peaked at $2.34M in Q4 2017.
130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2018.

Based on Shellback Capital's 13F filing for Q1 2018, filed 15 May 2018.